Investors / Japan / New Life Capital Partners
New Life Capital Partners
Venture capital · Tokyo, Japan · Asia Pacific
New Life Capital Partners is a Japanese venture capital firm that manages the New Life Science 1 fund, established in February 2019 with 10.1 billion yen. It provides financing to drug discovery ventures to help translate research from universities, research institutions and pharmaceutical companies into practical medicines.
Invests inHealthcare & Biotech
In its own wordsdrug discoverylife sciencesbiotechpharmaceuticalshealthcare
Your fit with New Life Capital Partners
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsNew Life Capital Partners lists 4 checked portfolio companies on its own site. Its largest theme is Healthcare & Biotech (100%). 100% of its companies are based in Japan.
No funding round on record names New Life Capital Partners yet, so the figures come from its portfolio page.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Hiroshima Venture Capital | 1 |
| OSAKA University Venture Capital | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers4100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Compare New Life Capital Partners head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Portfolio
4 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| F-Rest develops RNA editing therapies using endogenous ADAR | Healthcare & Biotech | Portfolio page | ||
| FunPep develops peptides for use in pharmaceuticals and cosmetics. | Healthcare & Biotech | Portfolio page | ||
| MiraBiologics develops new biopharmaceuticals using its LassoGraft Technology | Healthcare & Biotech | Portfolio page | ||
| The company develops regenerative medicine using mesenchymal stem cells. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- new-lifescience.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Companies checked
- 4
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get New Life Capital Partners' profile as data
Pull New Life Capital Partners' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/new-lifescience.com
# also
GET /v1/firms/new-lifescience.com/portfolio
GET /v1/firms/new-lifescience.com/coinvestors
GET /v1/firms/new-lifescience.com/news